Prednisone or Prednisolone ( DrugBank: Prednisone, Prednisolone )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
| 84 | Sarcoidosis | 2 |
66. IgA nephropathy
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01451710 (ClinicalTrials.gov) | March 2011 | 7/10/2011 | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | IgA Nephropathy | Drug: Prednisone or Prednisolone | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 30 | N/A | China |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03593759 (ClinicalTrials.gov) | January 15, 2019 | 27/6/2018 | Cardiac Sarcoidosis Randomized Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone or Prednisolone;Drug: Methotrexate | Ottawa Heart Institute Research Corporation | Canadian Institutes of Health Research (CIHR) | Recruiting | 18 Years | N/A | All | 194 | Phase 3 | United States;Canada;Japan;United Kingdom |
| 2 | NCT03324503 (ClinicalTrials.gov) | December 8, 2017 | 12/10/2017 | A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis | A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Glucocorticoid (prednisone or prednisolone) | Celgene | NULL | Completed | 18 Years | 65 Years | All | 8 | N/A | United States;Netherlands;United Kingdom |